Immunosuppuession in Behcet's disease: Clinical management and long-term visual outcome

• Tipo: Artigo em Revista Científica Internacional
• Data: 1995

Autores

Palmares, J (Autor) Outra; Castro Correia, J (Autor) Outra; Coutinho, MF (Autor) Outra; Araujo, D (Autor) Outra; Delgado, L (Autor) FMUP

Revista

Título: Ocular Immunology and Inflammation

Vol. 3

Páginas: 99-105

ISSN: 0927-3948

Editora: Taylor & Francis

Indexação

Scopus - 2 Citações

Outras Informações

ID Authenticus: P-007-6K4

DOI: 10.3109/09273949509085037

Abstract (EN): The authors review the visual prognosis of 44 patients with Behcet's disease referred to the Ophthalmology and Rheumatology Departments (Hospital S. Joao - one of the two major referral centers in Northern Portugal), due to ocular complaints or for routine examination, in the last ten years. All fulfilled the clinical criteria for diagnosis of Behcet's disease. Twenty-six were male and 18 female, with mean age 37 years (range 23-66). The mean evolution time since the first clinical manifestations was ten years (range 1-21). Aphthous stomatitis (100%) and genital ulcers (77.3%) were the initial manifestations preceding eye involvement. HLA-B51(5) was present in 27 of 36 typed patients (75%) Ocular manifestations were present in 33 patients (75%)-22 patients with panuveitis, eight with hypopyon, four with chronic anterior uveitis and three with episcleritis. Mean age of onset of ocular complications was 32 years (range 20-54). Retinal vaso-occlusive vasculitis was diagnosed in 26 patients (22 with panuveitis and four with posterior uveitis). To prevent ocular relapses, all needed immunosuppression with corticosteroids (drops, depo or systemic), combined with cyclosporine A (CsA) (5 mg/kg/day) in 13 patients and with chlorambucil or cyclophosphamide in six patients, when sight threatening uveitis had previously been refractory to treatment with systemic steroids. The 13 patients under CsA were observed for a period ranging from eight months to five years. Low-dose CsA was found to abrogate the intraocular inflammation, was well tolerated and had no major adverse effects. Regardless of the type of treatment, 21% (14/66) of the eyes lost useful vision five to ten years after initial diagnosis.

Idioma: Inglês

Tipo (Avaliação Docente): Científica